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ARTICLE
Performance of adjuvant treatment correlates 
with survival in reoperated glioblastomas
Uso de tratamento adjuvante é relacionado ao aumento da sobrevida em pacientes com 
glioblastoma submetidos à reoperação
Willey Gonçalves Zanovello1, Suzana M. F. Malheiros1, João Norberto Stavale2, Orestes P. Lanzoni1, Miguel M. 
Canteras1, Adrialdo J. Santos1, Felipe Slaviero1, Bruno Fernandes1, Sergio Cavalheiro1, Manoel A. de Paiva Neto1
Glioblastoma (GBM) is the most common primary 
tumor affecting the central nervous system and represents 
more than 50% of glial tumors1. In spite of the advances in 
microsurgery to accomplish optimized resections (exten-
sive, without worsening of the neurologic function), fol-
lowed by standard treatment with concomitant radio-
therapy (RT) and chemotherapy (CT) and maintenance 
therapy with temozolomide (TMZ)2, the patients’ survival 
remains rather limited, with small survival gains obtained 
in recent years3,4,5. 
The main factors associated with patient survival are age and 
functional status before surgery6,7; the extent of resection7,8, adju-
vant treatment7,9 and methylation of the O6-methylguanine-DNA 
methyltransferase (MGMT) promoter10, which also seem to be 
associated with increased survival. The role of surgical treatment 
for recurrence or regrowth of GBM has not yet been fully estab-
lished. While some authors recommend reoperation11,12,13, others 
did not find increased survival with this strategy14,15. 
Despite the large number of studies published in recent 
years demonstrating the benefits of reoperation in patients 
with recurrent GBM, we were not able to locate any simi-
lar study conducted in Brazil. Thus, we assessed a group of 
patients with recurrent GBM subjected to reoperation at a 
Brazilian public healthcare service aiming at describing the 
clinical characteristics of patients and identifying the ones 
who might benefit from this treatment modality. 
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ABSTRACT
Objective: To analyze cases of recurrent glioblastoma subjected to reoperation at a Brazilian public healthcare service. Methods: A total of 
39 patients subjected to reoperation for recurrent glioblastoma at the Department of Neurosurgery, São Paulo Hospital, Federal University 
of São Paulo, from January 2000 to December 2013 were retrospectively analyzed. Results: The median overall survival was 20 months 
(95% confidence interval – CI = 14.9–25.2), and the median survival after reoperation was 9.1 months (95%CI: 2.8–15.4). The performance 
of adjuvant treatment after the first operation was the single factor associated with overall survival on multivariate analysis (relative 
risk – RR = 0.3; 95%CI = 0.2–0.7); p = 0.005).  Conclusion: The length of survival of patients subjected to reoperation for glioblastoma at a 
Brazilian public healthcare service was similar to the length reported in the literature. Reoperation should be considered as a therapeutic 
option for selected patients. 
Keywords: glioblastoma;  reoperation; general surgery; survival. 
RESUMO
Objetivo: Analisar o papel da reoperação em pacientes com glioblastoma recidivado em um serviço público no Brasil. Métodos: Foram 
analisados retrospectivamente 39 pacientes submetidos à reoperação por recorrência de glioblastoma no Departamento de Neurocirurgia 
da Universidade Federal de São Paulo, no período de janeiro de 2000 até dezembro de 2013. Resultados: A sobrevida global mediana foi de 
20 meses (IC 95% = 14.9–25.2), e a sobrevida mediana após a reoperação foi de 9.1 meses (IC 95% =  2.8–15.4). A realização de tratamento 
adjuvante após a primeira cirurgia foi o único fator associado com a sobrevida global numa análise multivariada (RR = 0.3; IC 95% = 0.2–0.7; 
p  = 0.005).  Conclusão: A sobrevida dos pacientes submetidos à reoperação em um serviço público no Brasil é semelhante à reportada pela 
literatura. A reoperação deve ser considerada como uma opção terapêutica em pacientes selecionados. 
Palavras-chave: glioblastoma; reoperação; cirurgia geral; sobrevivência. 
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METHODS
We performed a retrospective and descriptive analysis 
of patients followed up at the Neurosurgery Section, who 
were diagnosed with GBM (World Health Organization grade 
IV) from January 2000 to December 2013 and subjected 
to reoperation due to tumor recurrence or regrowth. The 
patients were followed up until February 2015. 
The data were collected from the patients’ medi-
cal records and the database of the Neuro-oncology unit, 
Discipline of Neurosurgery, UNIFESP, having been treated by 
the same neuro-oncologist in a linear manner (SMFM). 
The study population included patients older than 
18 years of age, subjected to reoperation due to recurrence or 
progression of tumors diagnosed as GBM upon histopatho-
logical examination at the first operation. Patients subjected 
to only one biopsy in one of the surgeries, those who under-
went reoperation due to complications, and cases with miss-
ing data were excluded from the present study. 
The indication for reoperation was established in periodic 
multidisciplinary meetings that included neurosurgeons, 
neuro-oncologists, neurologists and neuroradiologists. 
Patients with Karnofsky Performance Status (KPS) scores 
equal to or higher than 70 and tumors likely to be entirely 
resected and located in non-eloquent brain areas were con-
sidered as candidates for reoperation. 
The variables analyzed were age, gender, initial symp-
tom, initial KPS score, duration of symptoms, tumor local-
ization, tumor laterality, extent of resection in both surgical 
procedures, localization of the recurrent tumor, time elapsed 
between the operations, adjuvant treatment after primary 
surgery and reoperation, delay in the onset RT, time of relapse 
relative to reoperation, overall survival (OS), survival after 
reoperation (SARp) and survival after relapse (SAR). 
The extent of resection was established based on com-
puted tomography and/or magnetic resonance imaging 
(MRI) of the brain, both with contrast and performed within 
the first 72 hours after surgery. Resection was considered to 
be total (TR) when non-linear contrast enhancement was 
not found in the control test and was considered partial (PR) 
when enhancement was found (presence of residual lesion). 
Recurrence was defined as the appearance of a new 
lesion in the control test of any patient subjected to TR, and 
regrowth as more than a 25% increase in residual lesions 
after the first operation. Spectroscopy and perfusion MRI 
were used in the differential diagnosis of pseudo-progression 
as per our service routine. Recurrence was considered to be 
local when it appeared in the same brain lobe as the primary 
tumor and as distant when it appeared in any other lobe or 
the contralateral brain hemisphere. Adjuvant treatment was 
defined as performance of RT and/or CT. Radiotherapy delay 
was defined as any interval longer than six weeks between 
the first operation and the onset of RT. 
Overall survival was defined as the time elapsed from 
the date of the first operation to death and SARp as the time 
elapsed from the date of reoperation to death. 
The study was approved by the research ethics committee 
of UNIFESP, ruling no. 1,093,864.
Statistical analysis
The categorical variables are expressed as percentages and the 
continuous ones as medians (ranges), as befitting. The event cumu-
lative curves were estimated using the Kaplan-Meier method and 
were compared via the log-rank test. The patients lost to follow-up 
were censored at their last follow-up visit, and patients who com-
pleted the study were censored in February 2015.  
Univariate and multivariate Cox regression was performed as 
needed. All variables with p < 0.1 on multivariate analysis or con-
sidered as having confirmed clinical relevance were included in 
the multivariate model. Multicollinearity problems were solved 
before including the variables in the model. The possible inter-
actions between the variables that were kept in the model were 
tested. The assumption of risk proportionality was tested using 
the Schoenfield residuals. The significance level was set as p < 0.05. 
Characteristics of the patients
A total of 167 patients were subjected to the same sur-
gical procedure. The data corresponding to 48 patients sub-
jected to reoperation for tumor recurrence or regrowth were 
initially included. However, nine patients had to be excluded 
because biopsy had only been performed in the first opera-
tion in six cases and the second biopsy in the other three. 
Thus, the sample included a total of 39 patients. 
Table 1 describes the demographic and clinical character-
istics of the included patients. Their median age was 49 years 
old (20 to 79 years old); 26 patients were male (66%). Headache 
was the most common initial symptom of disease, occurring 
in 23 patients (59%); followed by seizures, 11 cases (28%); and 
motor deficit, behavioral changes, dizziness and vomiting, one 
case each (3%). The median preoperative KPS score was 80, and 
the postoperative KPS score of the first surgery was 90 (assessed 
at the first follow-up visit). The median duration of symptoms 
from the date of the appearance of the first symptom to the first 
operation was eight weeks (ranging from one to 103 weeks).  
RESULTS
Table 2 describes the extent of resection in each operation 
and the interval of time between them. The first operation 
was classified as TR in 23 cases (59%) and as PR in 16 (41%). 
The second operation was classified as TR in 21 cases (54%) 
and as PR in 18 (46%). 
Recurrence was local in 34 cases (87%), distant in three 
(8%) and both local and distant in two cases (5%). The median 
time elapsed between the two operations was 4.7 months (0.7 
to 54.1 months).
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Five patients were subjected to a third operation, with 
three cases of TR and two of PR. 
The morbidity rate corresponding to the first operation was 
2.6%, with no cases of perioperative death. The morbidity rate 
corresponding to reoperation was 20.5% (eight patients): three 
cases of surgical wound infection that required surgical cleansing, 
one of which progressed into osteomyelitis; one patient exhibited 
transient hemihypesthesia; and four exhibited permanent neu-
rological aggravation, hemiplegia and aphasia in two cases, sleep-
iness and ataxia in one, and behavioral disorders in one.
Table 3 describes the data relative to adjuvant treatment. 
A total of 33 patients (83%) recieved CT, 18 (55%) using 
carmustine (bis-chloroethylnitrosourea, BCNU), 14 (42%) 
using TMZ and one (3%) using BCNU/procarbazine, lomus-
tine, and vincristine (PCV). It should be noted that TMZ 
became available in our service starting May 2009; from 
that moment onwards, only one out of 15 patients used 
BCNU due to social reasons, while all of the others were 
treated with TMZ. Among the 33 patients who used TMZ, 
11 (33%) received CT after reoperation only. The median 
time to onset of CT was 16 weeks. 
A total of 35 patients (88%) were subjected to RT, with a 
median dose of 60 Gy. The median time to onset of RT was 
eight weeks. Onset of RT was delayed beyond six weeks in 
29 cases (74%).  
Recurrence occurred before the onset of or in the course of 
RT in 18 cases (46%) and after the end of RT in 21 cases (54%). 
It should be noted that adjuvant treatment after reopera-
tion was not uniform. The patients who had received stan-
dard adjuvant treatment after the first operation (RT followed 
by CT with BCNU until 2009 and with TMZ afterwards) were 
indicated for additional CT and/or RT (maintenance of TMZ 
for a protracted regimen, bevacizumab or re-irradiation). 
In turn, the patients who had not been given adjuvant ther-
apy after the first operation were indicated for the standard 
regimen after reoperation. 
The median survival after reoperation was 9.1 months 
(95%CI = 2.8–15.4), and the median OS was 20 months 
(95%CI = 14.9–25.2). 
On univariate analysis, the variables associated with OS 
were performance of adjuvant treatment before the first 
operation (Figure 1) and an interval between operations lon-
ger than six months. On multivariate analysis, adjuvant treat-
ment after the first surgery was the only independent variable 
associated with OS (relative risk – RR = 0.3; 95%CI = 0.2–0.7; 
p = 0.005) after adjustment for KPS score, age and interval of 
time between operations (Table 4). 
On univariate analysis, the variables associated with 
SARp were TR at reoperation (RR = 0.3; 95%CI = 0.1–0.7; 
Table 1. Sociodemographic and clinical characteristics of the 
39 analyzed patients.
KPS: Karnofsky performance status.
Characteristics Number of patients 
Gender  
Male 26 (66%)
Female 13 (34%)
Median age 49 (20–79)
Initial KPS score
Median 80
< 70 9 (23%)
≥ 70 30 (77%)
Initial tumor localization
Right hemisphere 18 (46%)
Left hemisphere 21 (54%)
Temporal 11 (28%)
Frontal 10 (26%)
Parietal 2 (5%)
Occipital 1 (3%)
Multilobar 15 (38%)
Initial symptom
Headache 23 (59%)
Seizure 11 (28%)
Other 5 (13%)
Recurrence
Local 34 (87%)
Distant 3 (8%)
Local + distant 2 (5%)
Table 2. Extent of resection in each operation and interval of 
time between operations.
Operation Number of patients
First
TR 23 (59%)
PR 16 (41%)
Reoperation
TR 21 (54%)
PR 18 (46%)
Interval between operations
Median 4.7 months (0.7 to 54.1)
≤ 6 months 21 (54%)
> 6 months 18 (46%)
TR: total resection; PR: partial resection.
Table 3. Characteristics of adjuvant treatment. 
Adjuvant treatment Number of patients
Chemotherapy
No 9 (15%)
Yes 33 (85%)
BCNU 18 (55%)
TMZ 14 (42%)
BCNU/PCV 1 (3%)
Radiotherapy
No 4 (12%)
Yes 35 (88%)
Delay (> 6 weeks) 29 (74%)
BCNU: bis-chloroethylnitrosourea; TMZ: temozolomide; BCNU/PCV: bis-
chloroethylnitrosourea/ procarbazine, lomustine, and vincristine.
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p = 0.005) and adjuvant treatment after reoperation (RR = 0.4; 
95%CI = 0.2–0.8; p = 0.016). Multivariate analysis detected 
an interaction between those two variables. In the analysis 
stratified per extent of resection (Figure 2), relative to the 
group that received adjuvant treatment after reoperation, the 
median SARp was longer in the patients with subtotal resec-
tion at reoperation (p: 0.044). Relative to the patients with 
TR, adjuvant treatment after reoperation was not associated 
with longer SARp (p = 0.089).
Delayed onset of RT was not associated with OS in the 
analyzed sample of patients. Separate additional analysis of 
the patients in which onset of RT was delayed did not show 
any difference in OS between the ones who had tumor relapse 
before/during RT (15 cases) and the ones in whom the tumor 
had relapsed after the end of RT (14 cases), RR = 2.0 (95%CI = 
0.8-4.8; p = 0.11).
DISCUSSION
In the present study, we performed a descriptive analy-
sis of patients subjected to reoperation for recurrent GBM. 
Survival may be longer in our sample (20 months) compared 
to the median survival of patients with GBM reported in the 
literature, which varied from six to 18 months4,16. 
Role of reoperation in overall survival
In our study, the OS was 20 months, consistent with 
those found in the literature. McNamara et al.17 compared 
104 patients who underwent repeated surgery with 397 
who underwent primary surgery only and found that the OS 
was 21 months in the former versus 10 months in the latter 
(p < 0.001). Similar results were reported by Helseth et al.5, 
who analyzed a sample of 516 patients, with 56 subjected 
to reoperation; OS was longer in the latter compared to the 
ones who underwent primary surgery only, 18.4 months ver-
sus 8.6 months (p < 0.001). 
Role of reoperation in survival after recurrence (SAR)
Relative to the full study population, the median SARp in 
this study was 9.1 months. In the review Ryken et al.18 per-
formed in 2014, the average SARp was nine months, which is 
much longer than the one reported in the review by Barbagallo 
et al.11 from 2008, which ranged from three to five months. 
Ringel et al.7 analyzed 503 patients who underwent reoperation 
for active disease and found that the SARp was 11.9 months, 
while in the study by Quick et al.19, in which patients with KPS 
score > 60 and tumors likely to be entirely resected were sub-
jected to repeated surgery, the SARp was 13 months. 
Relevance of adjuvant treatment
In our study, performance of adjuvant treatment 
(RT and/or CT) before reoperation behaved as a prognostic fac-
tor for OS. Since 2009, all patients diagnosed with GBM at our 
institution have been indicated for adjuvant treatment based 
on the Stupp protocol2. However, as a function of problems 
inherent to the Brazilian health system, the tumors recurred 
in 41% of the patients before the adjuvant treatment was initi-
ated, a fact that was associated with reduced OS in that group 
compared to the cases in which the tumors recurred after 
adjuvant treatment (15.9 vs. 23.1 months; p: 0.008). 
The impact of adjuvant treatment resulting in longer sur-
vival of patients with GBM has been previously reported in 
the literature5,15,20,21. Stark et al.21 assessed 492 patients with 
GBM and found that RT and CT alone or in combination 
had an impact on OS. The same conclusion was reached by 
Filippini et al.15 in their study of 676 patients with GBM. 
Extent of resection at reoperation
Relative to survival after reoperation, the only indepen-
dent factors on both univariate and multivariate analy-
sis were the extent of resection at reoperation (RR = 0.3; 
95%CI = 0.1–0.7; p =  0.005) and performance of adjuvant 
treatment after reoperation (RR = 0.4; 95%CI = 0.2 –0.8; 
p = 0.016). Relative to the patients with TR at reoperation, the 
subsequent performance of adjuvant treatment did not exert 
any impact on SARp on multivariate analysis (p = 0.089). 
However, adjuvant treatment exerted an impact on SARp in 
the cases with PR at reoperation (p = 0.044). 
Yong et al.22 confirmed the relevance of the extent of 
resection at reoperation after finding that a residual tumor 
volume of less than 3 cm3 after reoperation exerted an 
impact on the patients’ survival: OS values were 20 months in 
patients with TR, 11 months in patients with residual tumor 
volume less than 3 cm3 and five months when the residual 
Figure 1.  Kaplan-Meier curve representing the overall survival 
(OS) of patients who did or did not receive adjuvant treatment 
after the first operation. 
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Table 4. Univariate and multivariate analyses relative to overall survival.
Variable (n)
Univariate analysis Median OS Multivariate analysis
RR 95%CI p value (Months) RR 95%CI p value
Gender
Male (26) 0.6 0.3–1.2 0.159 17     NS
Female (13) 1   -- 26      
Age
≥ 50 years old (18) 1.5 0.7–3.1 0.282 20.8     NS
< 50 years old (21) 1     19.1      
KPS score
≥ 70 (30) 1.3 0.5–3.3 0.528 20.1     NS
< 70 (9) 1     19.8      
Laterality
Right (18) 1.1 0.5–2.2 0.862 20.1     NS
Lobe (21) 1     19.8      
Frontal lobe localization
Yes (10) 1 0.5–2.0 0.929 20.8     NS
No (29) 1     20.1      
Temporal lobe localization
Yes (11) 1.3 0.6–2.6 0.531 17     NS
No (28) 1     21      
> 1 affected lobes
Yes (15) 0.9 0.4–1.8 0.68 19.1     NS
No (24) 1     20.8      
Interval between operations
≥ 6 months (18) 0.4 0.2–0.9 0.023 23.6     NS
< 6 months (21) 1     16.8      
RT delay
Yes (29) 1.3 0.6–3.0 0.467 20.1     NS
No (10) 1     17      
First operation resection
TR (23) 1.4 0.7–3.1 0.369 19.8     NS
PR (16) 1     20.8      
Reoperation resection
TR (21) 1.7 0.8–3.6 0.137 23.1     NS
PR (18) 1     16.8      
Adjuvant therapy after first operation
Yes (23) 0.4 0.2–0.8 0.008 23.1 0.3 0.2-0.7 0.005
No (16) 1     15.9 1    
Adjuvant therapy after reoperation
Yes (26) 1 0.5–2.2 0.903 23.1     NS
No (13) 1     19.8      
Recurrence
Distant (5) 2.4 0.7–8.1 0.148 25.9     NS
Local (34) 1     19.1      
RR: relative risk; CI: confidence interval; OS: Overall Survival; KPS: Karnofsky Performance Status; RT: radiotherapy; TR: total resection; PR: partial resection.
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tumor volume was larger than 3 cm3. Following a study with 
170 patients, Oppenlander et al.23 concluded that an extent 
of resection larger than 80% in repeated surgery suffices to 
increase patients’ survival. 
Influence of radiotherapy delay on survival
To assess the influence of RT delay on survival, we com-
pared the patients who had started RT within the first six 
weeks after surgery (no delay) to those who had started it 
more than six weeks afterwards (RT delay) and found no 
difference in their survival (RR = 1.3; 95%CI = 0.6; p = 0.467). 
We chose that time interval because it was the one adopted 
in previous studies24,25. Our findings in this regard agree with 
data reported in the literature24,26. Although some authors 
found that RT delay has negative effects on OS25,27 this topic 
remains controversial. In turn, Loureiro et al.28 assessed the 
time elapsed from surgery to onset of RT at one public and 
one private healthcare service in Brazil and also failed to find 
any difference in OS in association with delayed RT (RR = 1.2; 
95%CI = 0.8 –1.8; p = 0.470).
Delay in the onset of RT is mainly due to the increase in 
the demand for this treatment modality as a function of pop-
ulation aging, with consequent elevations in the incidence 
rates of various types of cancer29. While difficulty in meet-
ing the demand is encountered in developed countries, it is 
much more frequent in developing countries, especially in 
the public healthcare setting28. In Brazil, the situation is espe-
cially worrisome, as the increasing demand for RT created 
an inefficient system; thus, only 65.9% of the patients need-
ing RT actually receive it, having to wait a median interval of 
almost four months, independent of the type of cancer28. Our 
service represents a classic example of these problems: onset 
of RT was delayed in 74% of the patients analyzed in the pres-
ent study: the median interval from surgery to onset of RT 
was eight months. One of the patients in our sample had to 
wait 23 weeks (5.3 months) to start RT.  
Nevertheless, upon analyzing the subgroup of patients 
with delayed RT, no difference was found in OS between 
the patients with tumor recurrence before/during RT and 
the ones in whom the tumor recurred after the end of RT 
(RR =  2.0; 95%CI  = 0.8 –4.8; p = 0.11). Thus, we are also led 
to believe that the patients with tumor relapse before or dur-
ing RT are candidates for reoperation. That is, reoperation 
of patients who relapsed before RT due to treatment delay 
afforded the opportunity to conduct adjuvant treatment. 
Study limitations
Our study exhibits some limitations, including small sam-
ple size; retrospective data collection; lack of uniformity in 
the adjuvant treatment instituted after the first and second 
operations; selection bias, as only patients with KPS scores 
over 70 and lesions considered to be surgically accessible 
were subjected to reoperation; and the fact that we did not 
compare the patients subjected to re-resection to others who 
did not undergo a second surgery. 
Future perspectives
Among the most promising treatments for GBM, tar-
geted molecular therapies have been widely investigated 
in recent years. However, no effective results have yet been 
achieved. Intratumor heterogeneity and the heterogene-
ity between the primary and recurrent tumors represent 
significant limitations to the success of this type of thera-
peutic approach. Collecting samples of the relapsed tumor, 
Figure 2. (A) Kaplan-Meier curve representing the Survival after reoperation (SARp) of patients subjected to parcial resection (PR) 
at reoperation and who did or did not receive adjuvant treatment after reoperation. (B) Kaplan-Meier curve representing the SARp 
of patients subjected to total Resection (TR) at reoperation and who did or did not receive adjuvant treatment after reoperation. 
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whenever possible, is crucial to advance not only in the 
assessment of the response to targeted therapies but also in 
the understanding of the mechanisms of resistance to treat-
ment30. In this regard, reoperation, provided it is safe, will 
likely become an essential component of the management 
of these patients in the future. 
In conclusion, despite the limitations of our study, 
we sought to describe the actual conditions of the treatment 
of recurrent glioblastoma at a Brazilian public healthcare ser-
vice. In many developing countries, therapeutic alternatives 
and targeted therapies remain obscure but keeping in mind 
factors such as age, KPS prior to and after surgery, degree of 
resection TR vs. PR and adjuvant RT and CT can still pro-
vide results comparable to modern day series. In spite of the 
delays and difficulties that conspired against the achieve-
ment of the ideally complete treatment, the length of survival 
of patients who underwent reoperation was similar to those 
reported in the literature. Our results indicate that reopera-
tion is feasible and may be considered a treatment option for 
a select group of patients with recurrent GBM in Brazil. 
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